Back to Search
Start Over
Additive Benefits of Pravastatin and Aspirin to Decrease Risks of Cardiovascular Disease
- Source :
- Archives of Internal Medicine. 164:40
- Publication Year :
- 2004
- Publisher :
- American Medical Association (AMA), 2004.
-
Abstract
- Background In randomized trials of secondary prevention, pravastatin sodium and aspirin reduce risks of cardiovascular disease. Pravastatin has a predominantly delayed antiatherogenic effect, and aspirin has an immediate antiplatelet effect, raising the possibility of additive clinical benefits. Methods In 5 randomized trials of secondary prevention with pravastatin (40 mg/d), comprising 73 900 patient-years of observation, aspirin use was also prescribed in varying frequencies, and data were available on a large number of confounding variables. We tested whether pravastatin and aspirin have additive benefits in the 2 large trials (Long-term Intervention With Pravastatin in Ischaemic Disease trial and the Cholesterol and Recurrent Events trial) that were designed to test clinical benefits. We also performed meta-analyses of these 2 trials and 3 smaller angiographic trials that collected clinical end points. In all analyses, multivariate models were used to adjust for a large number of cardiovascular disease risk factors. Results Individual trials and all meta-analyses demonstrated similar additive benefits of pravastatin and aspirin on cardiovascular disease. In meta-analysis, the relative risk reductions for fatal or nonfatal myocardial infarction were 31% for pravastatin plus aspirin vs aspirin alone and 26% for pravastatin plus aspirin vs pravastatin alone. For ischemic stroke, the corresponding relative risk reductions were 29% and 31%. For the composite end point of coronary heart disease death, nonfatal myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, or ischemic stroke, the relative risk reductions were 24% and 13%. All relative risk reductions were statistically significant. Conclusion More widespread and appropriate combined use of statins and aspirin in secondary prevention of cardiovascular disease will avoid large numbers of premature deaths.
- Subjects :
- Male
medicine.medical_specialty
law.invention
Randomized controlled trial
Risk Factors
law
Internal medicine
Internal Medicine
medicine
Humans
Myocardial infarction
Aged
Pravastatin
Randomized Controlled Trials as Topic
Aspirin
business.industry
Surrogate endpoint
Anticholesteremic Agents
nutritional and metabolic diseases
Middle Aged
medicine.disease
Surgery
Stroke
Clinical trial
Pravastatin Sodium
Cardiovascular Diseases
Relative risk
Multivariate Analysis
Cardiology
Drug Therapy, Combination
Female
business
Platelet Aggregation Inhibitors
medicine.drug
Subjects
Details
- ISSN :
- 00039926
- Volume :
- 164
- Database :
- OpenAIRE
- Journal :
- Archives of Internal Medicine
- Accession number :
- edsair.doi.dedup.....0b0a91bcca1a4ab55381e2e317d39b8d
- Full Text :
- https://doi.org/10.1001/archinte.164.1.40